Abstract
The aim of this study is to evaluate the impact of the COVID-19 pandemic in patients with NVAF receiving anticoagulant treatment with vitamin K antagonists (VKA) or new direct-acting oral anticoagulants (NOAC) in clinical practice in Spain.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have